Kronos Bio, Inc. Stock: price and insider trades · United States

Kronos Bio, Inc. is a U.S.-listed biopharmaceutical company traded on the Nasdaq under ticker KRON, placing it squarely on the NASDAQ market in the United States. The company was incorporated in Delaware on June 2, 2017, and built its business around a focused scientific thesis: targeting deregulated transcription, a disease biology that is implicated in cancer and, in broader research terms, autoimmune disorders as well. Kronos Bio’s historical footprint included a corporate headquarters in San Mateo, California, and a research facility in Cambridge, Massachusetts, a common structure for U.S. biotechs that combine executive and financing functions with proximity to major life-science talent and academic ecosystems.

From an operating perspective, Kronos Bio has been a clinical-stage biopharmaceutical developer rather than a commercial-stage revenue producer. Its core activity has centered on discovering and advancing small-molecule therapeutics designed to modulate transcriptional regulatory networks. The company’s public pipeline has included clinical and preclinical assets, with programs such as KB-0742, an orally bioavailable CDK9 inhibitor developed for transcriptionally addicted solid tumors, and earlier-stage programs including lanraplenib and additional internally discovered candidates. This strategy reflects a differentiated, mechanism-driven approach: instead of competing broadly in crowded oncology categories, Kronos Bio aimed at biologically validated but technically challenging targets that may offer selective therapeutic leverage.